{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:55:54Z","timestamp":1773788154989,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In the last 5\u00a0years, there has been a significant focus on the use of positron emission tomography (<jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>) for primary and secondary staging of prostate cancer. In this study, we aim to describe the trends of use between Gallium\u201068 prostate\u2010specific membrane antigen ligand (Ga\u201068 <jats:styled-content style=\"fixed-case\">PSMA<\/jats:styled-content>) <jats:styled-content style=\"fixed-case\">PET<\/jats:styled-content>\/computed tomography (<jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content>) and nuclear medicine bone scan (<jats:styled-content style=\"fixed-case\">NMBS<\/jats:styled-content>) for prostate cancer staging in the first institution in Australia to offer both modalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated trends in prostate cancer staging\/restaging imaging modalities at our facility between the time period January 2013\u2013April 2018. Imaging logs were filtered to identify <jats:styled-content style=\"fixed-case\">NMBS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> scans done within the time period for prostate cancer. Sub\u2010analysis was undertaken (i) to investigate the number of patients who were imaged using both modalities, (ii) to compare the age of the patients in the <jats:styled-content style=\"fixed-case\">NMBS<\/jats:styled-content> group and the <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> group and (iii) to compare the use of <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> for pre\u2010treatment staging compared to the detection of recurrence or metastatic disease (secondary staging).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3144 examinations were performed in the time period reviewed, with 546 <jats:styled-content style=\"fixed-case\">NMBS<\/jats:styled-content> and 2598 <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> scans performed. In the 6\u00a0months after <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> was introduced, there was a 45.7% decrease in the number of <jats:styled-content style=\"fixed-case\">NMBS<\/jats:styled-content> performed and 95.3% decrease across the duration of the study. In the <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> cohort, 1569 examinations were performed for pre\u2010treatment staging and 1029 performed for secondary staging. There was a significant difference in the proportion of <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> conducted for pre\u2010treatment staging compared with secondary staging when comparing the first and final 500 examinations (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>After the introduction of <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> there was a marked decline in the use of <jats:styled-content style=\"fixed-case\">NMBS<\/jats:styled-content> for prostate cancer staging. This finding is of note as it occurred before there was clinical data or guidelines supporting the use of <jats:styled-content style=\"fixed-case\">PSMA PET<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> for prostate cancer imaging.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.12885","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T01:47:32Z","timestamp":1555033652000},"page":"495-499","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Five\u2010year trends of bone scan and prostate\u2010specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-4428","authenticated-orcid":false,"given":"Crishan","family":"Haran","sequence":"first","affiliation":[{"name":"School of Medicine University of Queensland Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-7385","authenticated-orcid":false,"given":"Rhiannon","family":"McBean","sequence":"additional","affiliation":[{"name":"Wesley Medical Imaging The Wesley Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6053-8174","authenticated-orcid":false,"given":"Rex","family":"Parsons","sequence":"additional","affiliation":[{"name":"Wesley Medical Imaging The Wesley Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wong","sequence":"additional","affiliation":[{"name":"Wesley Medical Imaging The Wesley Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2706"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.043"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5465"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/893193"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00785-9"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000123981.03084.06"},{"key":"e_1_2_5_10_1","first-page":"2191","article-title":"Comparison of radionuclide bone scans and magnetic resonance imaging in detecting spinal metastases","volume":"34","author":"Gosfield E","year":"1993","journal-title":"J Nucl Med"},{"key":"e_1_2_5_11_1","first-page":"1623","article-title":"Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET","volume":"40","author":"Schirrmeister H","year":"1999","journal-title":"J Nucl Med"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.177.1.1770229"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2007.05.022"},{"key":"e_1_2_5_14_1","first-page":"580","article-title":"Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature","volume":"4","author":"Yu CY","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"e_1_2_5_15_1","first-page":"81","article-title":"Prostate\u2010specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver DA","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12779-1"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.021"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2016.11.002"},{"key":"e_1_2_5_20_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2013"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.08.003"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.01.002"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.11.095"},{"key":"e_1_2_5_24_1","volume-title":"Prostate Cancer: Diagnosis and Management [CG175]","author":"The National Institute for Health and Care Excellence","year":"2014"},{"key":"e_1_2_5_25_1","volume-title":"Prostate Cancer Arnhem","author":"European Association of Urology","year":"2018"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13616"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2497-y"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2298-2"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-013-2525-5"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1754-9485.12885","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12885","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1754-9485.12885","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T15:50:07Z","timestamp":1694274607000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.12885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/1754-9485.12885"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.12885","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"2018-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}